

**Listing of Claims**

1-16 Canceled

17. (Currently amended) A method of delivering an agent into the central nervous system of an animal comprising administering to said animal a conjugate comprising said agent conjugated to a megalin-binding RAP fragment that comprises an amino acid sequence at least 80% identical to amino acids 221-323 of RAP (Figure 15) megalin-binding moiety, wherein the transport of said agent conjugated to said megalín-binding RAP fragment megalín-binding moiety across the blood brain barrier of said animal is greater than the transport of said agent in the absence of said conjugation to said megalín-binding moiety.

18. (Currently amended) A method of increasing transcytosis of an agent across the blood-brain barrier of an animal, comprising administering to said animal a conjugate comprising conjugating said agent conjugated to a megalin-binding RAP fragment that comprises an amino acid sequence at least 80% identical to amino acids 221-323 of RAP (Figure 15) to a megalín-binding moiety, wherein transcytosis of said agent when conjugated to said megalín-binding RAP fragment megalín-binding moiety is greater than the transcytosis of said agent in the absence of said conjugation.

19. (Currently amended) A method of treating a disorder of the CNS in a mammal comprising administering to said animal a conjugate comprising a therapeutic agent conjugated to a megalin-binding RAP fragment that comprises an amino acid sequence at least 80% identical to amino acids 221-323 of RAP (Figure 15) a megalín-binding moiety.

20. Canceled

21. (Currently amended) The method of claim 19 claim-20, wherein said disorder is selected from the group consisting of Huntington's Disease, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, ischemia-related disease and stroke, spinal muscular atrophy, cerebellar degeneration, perivenous encephalitis, schizophrenia, epilepsy and a central nervous system cancer.

22. (Withdrawn) The method of claim 21, wherein said disorder is a central nervous system cancer and said agent is a cancer chemotherapeutic agent.

23-57. Canceled

58. (Previously presented) The method of claim 17 or 18 wherein the animal is a human.

59. (Previously presented) The method of claim 58 wherein the human is suffering from a disorder selected from the group consisting of Huntington's Disease, Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, ischemia-related disease and stroke, spinal muscular atrophy, cerebellar degeneration, perivenous encephalitis, schizophrenia, epilepsy and a central nervous system cancer.

60. (Previously presented) The method of claim 17 or 18 wherein the agent is a neurotrophic factor.

61. (Previously presented) The method of claim 17 or 18 wherein the therapeutic agent is a neurotrophic factor selected from the group consisting of Glial-Derived Neurotrophic Factor, Nerve Growth Factor, Brain-Derived Neurotrophic Factor, Neurotrophin-3, Neurotrophin-4/5, aFGF, bFGF, CNTF, Leukaemia Inhibitory Factor, Cardiotrophin-1, TGFb, BMPs, GDFs, Neurturin, Artemin, Persephin, EGF, TGFa, Neuregulins, IGF-1, IGF-2, ADNF and PDGF.

62. (Previously presented) The method of claim 17 or 18 wherein the therapeutic agent is brain-derived neurotrophic factor (BDNF).